HPIP expression predicts chemoresistance and poor clinical outcomes in patients with epithelial ovarian cancer.
This study aims to investigate the expression of the hematopoietic pre-B-cell leukemia transcription factor-interacting protein (HPIP) and its association with platinum resistance in epithelial ovarian cancer (EOC). The protein expression of HPIP was analyzed by immunohistochemistry in 248 patients with EOC. Furthermore, we analyzed the association between HPIP expression and clinicopathological features including prognosis in EOC samples. High HPIP expression was correlated with platinum resistance in EOCs. HPIP in platinum-resistant cases was overexpressed compared with that in platinum-sensitive cases (P<.001). Platinum resistance was independently correlated with the International Federation of Gynecology and Obstetrics stage and HPIP overexpression. High HPIP expression was positively correlated with International Federation of Gynecology and Obstetrics stage, histologic grade, residual tumor size, lymph node metastasis, serum levels of CA125, and poor prognosis. Our findings indicate that HPIP overexpression is an independent predictor of platinum-based chemotherapy resistance and that it may also be a potential biomarker for targeted therapy.
Department of Gynecology, the Affiliated Tumor Hospital, Harbin Medical University, 150081 Harbin, China; Department of Gynaecology and Obstetrics, The General Hospital of Daqing Oil Field, 163000 Daqing, China.
Yao
Y
Wang
Department of Gynaecology and Obstetrics, The General Hospital of Daqing Oil Field, 163000 Daqing, China.
Mingxun
M
Li
Department of Gynecology, the Affiliated Tumor Hospital, Harbin Medical University, 150081 Harbin, China. Electronic address: dr_mfl1979@126.com.
Fanling
F
Meng
Department of Gynecology, the Affiliated Tumor Hospital, Harbin Medical University, 150081 Harbin, China. Electronic address: doctorlouge@126.com.
Ge
G
Lou
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D014408:Biomarkers, Tumor / Q000032:analysis* / Q000097:blood; D001706:Biopsy; D018394:CA-125 Antigen / Q000097:blood; D000077216:Carcinoma, Ovarian Epithelial; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D047908:Intracellular Signaling Peptides and Proteins / Q000032:analysis*; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008565:Membrane Proteins / Q000097:blood; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000737:chemistry* / Q000188:drug therapy* / Q000473:pathology; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000188:drug therapy* / Q000473:pathology; D017671:Platinum Compounds / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D016016:Proportional Hazards Models; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden; D015854:Up-Regulation
D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; C469750:HCFC1R1 protein, human; D047908:Intracellular Signaling Peptides and Proteins; C451759:MUC16 protein, human; D008565:Membrane Proteins; D017671:Platinum Compounds
Epithelial ovarian cancer; HPIP; Immunohistochemistry; Platinum resistance